Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Aug 14;9(8):e105007.
doi: 10.1371/journal.pone.0105007. eCollection 2014.

Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study

Affiliations
Observational Study

Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study

Heiko Rühl et al. PLoS One. .

Abstract

Introduction: The increased thrombotic risk of oral contraceptives (OC) has been attributed to various alterations of the hemostatic system, including acquired resistance to activated protein C (APC). To evaluate to what extent OC-associated APC resistance induces a prothrombotic state we monitored plasma levels of thrombin and molecular markers specific for thrombin formation in women starting OC use. Elevated plasma levels of thrombin have been reported to characterize situations of high thrombotic risk such as trauma-induced hypercoagulability, but have not yet been studied during OC use.

Patients and methods: Blood samples were collected prospectively from healthy women (n = 21) before and during three menstruation cycles after start of OC. APC resistance was evaluated using a thrombin generation-based assay. Plasma levels of thrombin and APC were directly measured using highly sensitive oligonucleotide-based enzyme capture assay (OECA) technology. Thrombin generation markers and other hemostasis parameters were measured additionally.

Results: All women developed APC resistance as indicated by an increased APC sensitivity ratio compared with baseline after start of OC (p = 0.0003). Simultaneously, plasma levels of thrombin, prothrombin fragment 1+2, and of thrombin-antithrombin complexes did not change, ruling out increased thrombin formation. APC plasma levels were also not influenced by OC use, giving further evidence that increased thrombin formation did not occur.

Conclusions: In the majority of OC users no enhanced thrombin formation occurs despite the development of APC resistance. It cannot be ruled out, however, that thrombin formation might occur to a greater extent in the presence of additional risk factors. If this were the case, endogenous thrombin levels might be a potential biomarker candidate to identify women at high thrombotic risk during OC treatment. Large-scale studies are required to assess the value of plasma levels of thrombin as predictors of OC-associated thrombotic risk.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Change of the APC sensitivity ratio during the study period.
Box-whisker plots show the ratio [ETP+APC/ETP−APC] at visits 1–4. The center horizontal solid line is drawn at the median. Top and bottom edges of the boxes are located at the sample 75th and 25th percentiles. Top and bottom of the whiskers are located at the 90th and 10th percentiles. Each outlier is shown. P values indicate the changes of visits 2–4 compared to visit 1.
Figure 2
Figure 2
A. Thrombin plasma levels, determined by OECA; Limit of quantification (LOQ, solid line), 0.039 ng/ml; Limit of detection (LOD, dotted line), 0.017 ng/ml. B. APC plasma levels, determined by OECA; LOQ (solid line), 0.116 ng/ml; LOD (dotted line), 0.022 ng/ml.
Figure 3
Figure 3. Changes of variables during the study period.
Columns show the median. Parameters with significant changes between visit 1 and visit 4 are listed. P values indicate the changes of visits 2–4 compared to visit 1. *indicates highly significant changes of p<0.005.

References

    1. de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Heimerhorst FM, et al. (2014) Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014, Mar 3 (3) CD010813 doi: 10.10021/14651858.pub2 - DOI - PMC - PubMed
    1. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P (2012) Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf 35: 191–205. - PubMed
    1. Crawley JT, Zanardelli S, Chion CK, Lane DA (2007) The central role of thrombin in hemostasis. J Thromb Haemost 5 Suppl 195–101. - PubMed
    1. Dahlbäck B, Villoutreix BO (2005) The anticoagulant protein C pathway. FEBS Lett 579: 3310–3316. - PubMed
    1. Castoldi E, Rosing J (2010) APC resistance: biological basis and acquired influences. J Thromb Haemost 8: 445–453. - PubMed

Publication types

Substances

Supplementary concepts